ClinicalTrials.gg
RecruitingNCT06401356Updated Nov 12, 2026

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

A Phase 3 interventional study of Pelabresib and Ruxolitinib in Hematologic Malignancy, Solid Tumor and Advanced Malignancies, sponsored by Novartis Pharmaceuticals. Recruiting at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Hematologic Neoplasms by Novartis — 1 open to participants now, 1 under way, 1 of them phase 3. Hematologic Neoplasms · Novartis.

Planned enrollment
9th of 18
50 · median 49
Started
2024
the only one that year
Phase 3
4 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies in Hematologic Neoplasms by Novartis, this one is the 9th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 3, and was the 18th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

1 of the 18 studies in Hematologic Neoplasms by Novartis is open now, in 5 countries.

By country, each count listing its studies:

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hematologic Neoplasms by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).

Read the detailed description

The study will collect and monitor ongoing efficacy information with regard to disease and survival status, as well as safety information with regard to AEs, including SAEs and AEs of special interest (AESI).

Patients are eligible to continue pelabresib treatment as long as the regimen is tolerated, and the patient does not meet any of the discontinuation criteria.

Patients who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

There will be an eligibility check period of up to 28 days for this extension study. Patients who fulfill the inclusion and exclusion criteria are eligible for the study. After the patient willingly provides consent, eligibility will be assessed by the investigator and treatment with pelabresib can be started at the same dose and dosing schedule that was applied in the parent study in the last cycle prior to EOT unless there is need for dose adjustment due to toxicity.

A patient is considered to have completed the study after completion of all visits as defined in the Schedule of Assessments (SoA) as per protocol, including the Safety Follow-up visit and Survival Follow-up.

The Safety Follow-up period is the interval between the EOT visit and the scheduled Safety Follow-up visit, which should occur 30 days (±3 days) after the last dose of pelabresib. For patients who switch from investigational pelabresib to commercial pelabresib treatment, the Safety Follow-up period is the time from the last dose of investigational pelabresib until the first dose of commercial pelabresib. The treatment start date with commercial pelabresib will be considered the date of "early Safety Follow-up termination." All patients will be followed for AEs and SAEs for 30 days (±3 days) following the last dose of pelabresib on the extension study or until the initiation of a new anticancer therapy, whichever occurs first.

Reasonable efforts should be made to have the patient return for the Safety Follow-up visit and review any AEs that may occur during this period. If the patient cannot return to the site for the Safety Follow-up visit, then the patient should be contacted by telephone for assessment of AEs.

The end of study will occur when all parent studies have been closed with no further patients expected to be enrolled into the extension study, and all patients are either discontinued or study treatment becomes commercially available and reimbursed, or an alternate access program becomes available, whichever comes first. Prior to study completion, all patients should.have completed the Safety Follow-up visit or have been designated as lost to follow-up, died, or have withdrawn consent, whichever comes first. The sponsor reserves the right to close a study site or terminate the study at any time for any reason at the sole discretion of the sponsor.

03

Conditions studied

  • Hematologic Malignancy
  • Solid Tumor
  • Advanced Malignancies
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide signed , agreeing to all protocol and ICF requirements.
  • At least 18 years old and legally able to consent in the study's jurisdiction.
  • Previously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.
  • Demonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.
  • Willing and able to follow all study visits, treatments, and procedures.
  • Agree to avoid pregnancy or fathering children:

    • Men: Must use highly effective (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.
    • Women of (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.
    • Women not of childbearing potential (surgically sterile or ≥12 months without other cause) are eligible.

Note: Women with amenorrhea due to chemo/radiotherapy are considered WOCBP and must use contraception.

Additional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:

  • On a stable dose of ruxolitinib for ≥8 weeks
  • Has adequate bone marrow and organ function as defined by the following local laboratory values:

    • ≥ 1 × 10\^9/L in the absence of growth factors for the previous 4 weeks
    • count ≥ 75 × 10\^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
    • Peripheral blood blast count \< 5%
    • and/or ALT ≤ 2.5 × of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
    • Serum direct \< 2.0 × ULN of the local reference interval
    • Calculated or measured of ≥ 45 mL/min
  • Does not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study

Exclusion criteria

Exclusion Criteria:

  • Legally institutionalized or under judicial protection.
  • Enrolled in another interventional clinical trial (excluding the parent study).
  • History of to pelabresib, its , or similar drugs.
  • Significant gastrointestinal issues (e.g., active IBD, unresolved nausea/vomiting/diarrhea > Grade 1) that may affect drug absorption.
  • Any medical condition deemed unsuitable by the investigator.
  • Uncontrolled illness or condition that may compromise safety or protocol compliance.
  • Received systemic anticancer or treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea/anagrelide allowed up to 24 hours prior.)
  • Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.
  • Used strong inhibitors/inducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.
  • Received agents with systemic activity (>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of without systemic activity are eligible
  • Received a within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
  • Female participants who are pregnant, breastfeeding, or not using required .
  • Male participants who do not agree to use contraception or refrain from sperm donation as specified.
  • Unwilling or unable to comply with the study protocol.

Additional Exclusion Criterion for participants receiving ruxolitinib only treatment

  • Local access to commercially available and reimbursed ruxolitinib.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Pelabresib and/or ruxolitinib

    Participants who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study. Additionally, the MANIFEST-2 (NCT04603495) control group (i.e., treated with placebo + ruxolitinib) patients, will be offered pelabresib combination treatment at the time of enrollment if the investigator sees any potential benefit of adding pelabresib to ruxolitinib.

    Drug: Pelabresib · Drug: Ruxolitinib

Interventions

  • Small molecule inhibitor of bromodomain and extraterminal (BET) protein

    Also known as: CPI-0610

  • Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.

    Also known as: Jakavi™/Jakafi™

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs) and serious TEAEs

    To evaluate long-term safety in patients who are receiving pelabresib

    Time frame: 5 years

  2. Survival Follow-up

    Survival Follow-up consists of Survival and Leukemia-Free Survival Follow-up. All participants in the extension study will be followed up for Survival, while participants with hematological malignancies will be followed up for Survival and Leukemia-Free Survival.

    Time frame: 5 years

  3. Duration of Response (DoR)

    DOR defined as the time from the date of first response to the date of confirmed disease progression

    Time frame: 5 years

  4. Progression-free survival (PFS)

    PFS defined as the time from first dose to confirmed disease progression or death, whichever occurs first.

    Time frame: 5 years

  5. Leukemia-free survival (LFS)

    LFS defined as the time from first dose to the date of leukemic transformation or death, whichever occurs first.

    Time frame: 5 years

07

Study locations

15 of 15 sites recruiting
  • University of California LA
    Los Angeles, California 90095, United States
    Recruiting
    • Nicole Alimi NP · Contactnalimi@mednet.ucla.edu · +1 310 825 5513
    • Gary Schiller · Principal investigator
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
    • Tina Kothare · ContactKothare.Tina@mayo.edu · +1 904 953 6153
    • Candido Rivera · Principal investigator
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • Uni Of Michigan Health System
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • New York Presbyterian Hospital
    New York, New York 10021, United States
    Recruiting
  • Mt Sinai Medical Center
    New York, New York 10029-6574, United States
    Recruiting
    • Carly Sullivan · Contactcarly.sullivan@mssm.edu · +1 347 714 3285
    • Marina Kremyanskaya · Principal investigator
  • Novartis Investigative Site
    Antwerp, 2030, Belgium
    Recruiting
  • Novartis Investigative Site
    Bruges, 8000, Belgium
    Recruiting
  • Novartis Investigative Site
    Florence, FI 50134, Italy
    Recruiting
  • Novartis Investigative Site
    Varese, VA 21100, Italy
    Recruiting
  • Novartis Investigative Site
    Novara, 28100, Italy
    Recruiting
  • Novartis Investigative Site
    Amsterdam, 1081, Netherlands
    Recruiting
  • Novartis Investigative Site
    Cardiff, CF14 4XW, United Kingdom
    Recruiting
  • Novartis Investigative Site
    Glasgow, G12 0YN, United Kingdom
    Recruiting
  • Novartis Investigative Site
    London, SE1 7EH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2029, 64 months after the start.

Of 41 phase 3 interventional studies under Hematologic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 81. This study's planned 64 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2027 → Dec 2029 and completion Jun 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 6, 2024
StartActual
Aug 13, 2024
Primary completionEst.
Dec 31, 2029was Jun 2027
CompletionEst.
Dec 31, 2029was Jun 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2, 2027→Dec 31, 2029
Nov 12, 2026
Study completion
Jun 30, 2027→Dec 31, 2029
Nov 12, 2026
Eligibility
2 inclusion criteria edited, 10 added, 6 removed; 4 exclusion criteria added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedEligibility for Ongoing Pelabresib Treatment
  • EditedPreviously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.
  • EditedDemonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.
  • RemovedEligibility for Survival Follow-up
  • RemovedProvide signed informed consent, agreeing to all protocol and ICF requirements.
  • RemovedAre at least 18 years old and legally able to consent.
  • RemovedWere previously enrolled in a pelabresib clinical study.
  • RemovedAre willing and able to comply with follow-up procedures.
  • AddedAdditional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:
  • AddedOn a stable dose of ruxolitinib for ≥8 weeks
  • AddedHas adequate bone marrow and organ function as defined by the following local laboratory values:
  • AddedANC ≥ 1 × 10\^9/L in the absence of growth factors for the previous 4 weeks
  • AddedPlatelet count ≥ 75 × 10\^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
  • AddedPeripheral blood blast count < 5%
  • AddedAST and/or ALT ≤ 2.5 × ULN of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
  • AddedSerum direct bilirubin < 2.0 × ULN of the local reference interval
  • AddedCalculated or measured CrCl of ≥ 45 mL/min
  • AddedDoes not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study
Exclusion criteria
  • RemovedEligibility for Ongoing Pelabresib Treatment
  • AddedReceived immunosuppressive agents with systemic activity (>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of corticosteroids without systemic activity are eligible
  • AddedReceived a live vaccination within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
  • RemovedEligibility for Survival Follow-up • They are legally institutionalized or under judicial protection.
  • AddedAdditional Exclusion Criterion for participants receiving ruxolitinib only treatment
  • AddedLocal access to commercially available and reimbursed ruxolitinib.
Nov 12, 2026
Interventions
Added Drug: Ruxolitinib. Arm changed Pelabresib→Pelabresib and/or ruxolitinib
Nov 12, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionSurvival Follow-up: how it is measured was reworded
Nov 12, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • University of California LA · Los Angeles, United StatesContact •••5513→•••5513
  • Mayo Clinic Jacksonville · Jacksonville, United StatesContact •••6153→•••6153
  • Northwestern University · Chicago, United StatesContact •••1371→•••1371
  • New York Presbyterian Hospital · New York, United StatesContact •••2932→•••2932
  • Mt Sinai Medical Center · New York, United StatesContact •••3285→•••3285
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jun 2, 2027→Dec 31, 2029
    Study completion Jun 30, 2027→Dec 31, 2029
    Eligibility 2 inclusion criteria edited, 10 added, 6 removed; 4 exclusion criteria added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedEligibility for Ongoing Pelabresib Treatment
    • EditedPreviously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.
    • EditedDemonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.
    • RemovedEligibility for Survival Follow-up
    • RemovedProvide signed informed consent, agreeing to all protocol and ICF requirements.
    • RemovedAre at least 18 years old and legally able to consent.
    • RemovedWere previously enrolled in a pelabresib clinical study.
    • RemovedAre willing and able to comply with follow-up procedures.
    • AddedAdditional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:
    • AddedOn a stable dose of ruxolitinib for ≥8 weeks
    • AddedHas adequate bone marrow and organ function as defined by the following local laboratory values:
    • AddedANC ≥ 1 × 10\^9/L in the absence of growth factors for the previous 4 weeks
    • AddedPlatelet count ≥ 75 × 10\^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
    • AddedPeripheral blood blast count < 5%
    • AddedAST and/or ALT ≤ 2.5 × ULN of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
    • AddedSerum direct bilirubin < 2.0 × ULN of the local reference interval
    • AddedCalculated or measured CrCl of ≥ 45 mL/min
    • AddedDoes not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study
    Exclusion criteria
    • RemovedEligibility for Ongoing Pelabresib Treatment
    • AddedReceived immunosuppressive agents with systemic activity (>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of corticosteroids without systemic activity are eligible
    • AddedReceived a live vaccination within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
    • RemovedEligibility for Survival Follow-up • They are legally institutionalized or under judicial protection.
    • AddedAdditional Exclusion Criterion for participants receiving ruxolitinib only treatment
    • AddedLocal access to commercially available and reimbursed ruxolitinib.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionSurvival Follow-up: how it is measured was reworded
    Interventions Added Drug: Ruxolitinib. Arm changed Pelabresib→Pelabresib and/or ruxolitinib
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • University of California LA · Los Angeles, United StatesContact •••5513→•••5513
    • Mayo Clinic Jacksonville · Jacksonville, United StatesContact •••6153→•••6153
    • Northwestern University · Chicago, United StatesContact •••1371→•••1371
    • New York Presbyterian Hospital · New York, United StatesContact •••2932→•••2932
    • Mt Sinai Medical Center · New York, United StatesContact •••3285→•••3285
    + 4 other changes: index terms, identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06401356
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Aug 13, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CPI-0610

Start the discussion